Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Paul M. Ridker, MD, MPH, director of the Center for Cardiovascular Disease Prevention, and the Eugene Braunwald Professor of Medicine, cardiovascular medicine, Brigham and Women's Hospital, who presented the results of late-breaking study on residual inflammatory risk in contemporary statin treated patients. The study used an analyses of 31,197 patients in the PROMINENT, REDUCE-IT and STRENGTH trials. 

What new data can teach cardiologists about statin use and treating inflammation

"If we do not attack the inflammation, we just are not going to get the best outcomes for our patients," one researcher told Cardiovascular Business. 

Marielle Scherrer Crosbie and Tomas Neilan explain the STOP-CA trial and how statins can help prevent cardiotoxicity from anthracycline chemo agents.

Statins may help prevent anthracycline cardiotoxicity in chemotherapy

The STOP-CA trial showed that statins can help chemotherapy patients avoid potential side effects related to anthracycline agents. Co-principal investigators Marielle Scherrer-Crosbie, MD, and Tomas Neilan, MD, discussed the details of that trial at ACC.23. 

Thumbnail

Clopidogrel linked to better long-term outcomes than aspirin in PCI patients with and without diabetes

Clopidogrel is especially effective at limiting major adverse cardiovascular events among PCI patients with diabetes, researchers found. 

Antibiotic recalled due to risk of endocarditis, other life-threatening infections

According to an advisory on the FDA’s website, there is a “reasonable probability” that any immunocompromised patients exposed to the affected antibiotic could develop a life-threatening infection.

Thumbnail

FDA approves drug for children with rare condition causing high LDL cholesterol

Evkeeza, which was previously approved for patients ages 12 and above, was shown to help lower cholesterol for children with homozygous familial hypercholesterolemia (HoFH), in conjunction with other therapies. 


 

NASA astronaut Kate Rubins conducts research for the Effect of Microgravity on Drug Responses Using Engineered Heart Tissues (Cardinal Heart) investigation onboard the International Space Station, one of several cardiovascular experiments on the ISS in recent years. Two more cardiac experiements launched to the ISS in March 2023. NASA Image

Heart tissue heads to space for research on aging and impact of long spaceflights

These experiments, performed with help from NASA, are simply out of this world. 

Blood thinner recalled due to potential cancer risk

The recall, announced by the FDA, includes multiple lots of dabigatran etexilate capsules.

Steven Nissen, MD, chief academic officer of the Heart, Vascular and Thoracic Institute, Cleveland Clinic, explains the details from the late-breaking CLEAR Outcomes trial presented at the 2023 American College of Cardiology (ACC) meeting found bempedoic acid can be used in statin-intolerant patients to reduce low-density lipoprotein (LDL) cholesterol levels. #ACC #ACC23 Nexletol

CLEAR Outcomes trial shows statin-intolerant patients benefit from bempedoic acid

Steven Nissen, MD, spoke with Cardiovascular Business at ACC.23 about the late-breaking CLEAR Outcomes trial.

Displaying 137 - 144 of 290

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup